Apolipoprotein CI enhances the biological response to LPS via the CD14/TLR4 pathway by LPS-binding elements in both its N- and C-terminal helix

Jimmy F. P. Berbée, Claudia P. Coomans, Marit Westerterp, Johannes A. Romijn, Louis M. Havekes, and Patrick C. N. Rensen

Departments of General Internal Medicine, Endocrinology and Metabolic Diseases, and Cardiology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands; and Department of Biomedical Research, TNO-Quality of Life, Gauhuis Laboratory, 2301 CE Leiden, The Netherlands

Abstract Timely sensing of lipopolysaccharide (LPS) is critical for the host to fight invading Gram-negative bacteria. We recently showed that apolipoprotein CI (apoCI) (apoCI1-57) avidly binds to LPS, involving an LPS-binding motif (apoCI48-54), and thereby enhances the LPS-induced inflammatory response. Our current aim was to further elucidate the structure and function relationship of apoCI with respect to its LPS-modulating characteristics and to unravel the mechanism by which apoCI enhances the biological activity of LPS. We designed and generated N- and C-terminal apoCI-derived peptides containing varying numbers of alternating cationic/hydrophobic motifs. ApoCI1-38, apoCI1-30, and apoCI35-57 were able to bind LPS, whereas apoCI1-23 and apoCI46-57 did not bind LPS. In line with their LPS-binding characteristics, apoCI1-38, apoCI1-30, and apoCI35-57 prolonged the serum residence of 125I-LPS by reducing its activity of LPS. We designed and generated N- and C-terminal apoCI-derived peptides containing varying numbers of alternating cationic/hydrophobic motifs. ApoCI1-38, apoCI1-30, and apoCI35-57 were able to bind LPS, whereas apoCI1-23 and apoCI46-57 did not bind LPS. In line with their LPS-binding characteristics, apoCI1-38, apoCI1-30, and apoCI35-57 prolonged the serum residence of 125I-LPS by reducing its association with the liver. Accordingly, both apoCI1-38 and apoCI35-57 enhanced the LPS-induced TNFα response in vitro (RAW 264.7 macrophages) and in vivo (C57BL/6 mice). Additional in vitro studies showed that the stimulating effect of apoCI on the LPS response resembles that of LPS-binding protein (LBP) and depends on CD14/Toll-like receptor 4 signaling. We conclude that apoCI contains structural elements in both its N-terminal and C-terminal helix to bind LPS and to enhance the proinflammatory response toward LPS via a mechanism similar to LBP. — Berbée, J. F. P., C. P. Coomans, M. Westerterp, J. A. Romijn, L. M. Havekes, and P. C. N. Rensen. Apolipoprotein CI enhances the biological response to LPS via the CD14/TLR4 pathway by LPS-binding elements in both its N- and C-terminal helix. J. Lipid Res. 2010. 51: 1943–1952.

Supplementary key words peptide • inflammation • endotoxins • TNFα • mice

Lipopolysaccharide (LPS) is a major constituent of the outer membrane of Gram-negative bacteria. LPS molecules can be released from the outer membrane upon death or rapid growth and signal the presence of these bacteria in the circulation via activation of the myeloid differentiation protein-2 (MD2)-Toll-like receptor 4 (TLR4)-complex on monocytes/macrophages and endothelial cells (1–6). Timely sensing of LPS by inflammatory cells to stimulate the inflammatory response toward LPS and bacteria is crucial for activation of the host defense system to fight Gram-negative infection (7). If the initial antibacterial inflammatory response is inadequate or too late, uncontrolled bacterial growth will occur with excessive release of LPS into the circulation. This will lead to an exaggerated systemic host response with respect to excessive production of inflammatory mediators, which can ultimately result in the serious and life-threatening symptoms of septic shock (8, 9).

Apolipoprotein CI (apoCI) is the smallest identified apolipoprotein (57 amino acids) and is unusually rich in Lys residues. ApoCI has classically been recognized as an inhibiting factor for lipoprotein clearance by affecting LPL-mediated processing (10, 11) and subsequent receptor-mediated uptake of lipoproteins by the liver (12, 13). ApoCI contains two amphipathic α-helices (apoCI29 and apoCI38-52) that are separated by a flexible linker (apoCI39–37), with no substantial intramolecular interactions (Fig. 1). By virtue of these properties, apoCI has a boomerang shape similar to the LPS-binding protein bactericidal/permeability increasing protein (BPI) (14, 15),

Abbreviations: ApoCI, apolipoprotein CI; BPI, bactericidal/permeability increasing protein; CAP-18, cationic antimicrobial peptide-18; LALF, Limulus anti-lipopolysaccharide factor; LBP, lipopolysaccharide-binding protein; Lf, lactoferrin; LPL, lipoprotein lipase; LPS, lipopolysaccharide; MD2, myeloid differentiation protein-2; TLR4, Toll-like receptor 4; TNFα, tumor necrosis factor α.

© 2010 by the American Society for Biochemistry and Molecular Biology, Inc.
This article is available online at http://www.jlr.org

Journal of Lipid Research Volume 51, 2010 1943
levels positively correlate with an enhanced inflammatory response during endotoxemia (21) and with increased infection-related survival (17, 22).

We previously noted that the Lys-rich KVKEKLK motif (apoCI48–54) is highly homologous to the motifs in the proposed LPS-binding regions of the LPS-binding proteins Limulus anti-LPS factor (LALF) (LALF43-49; KWKYKGK) (23) and cationic antimicrobial peptide-18 (CAP-18) (CAP18117–123; KIKEKLK) (24) (Table 1). In fact, we have demonstrated that replacement of the Lys residues within this motif by Ala residues (i.e., AVAEALA), which neutralizes positive charges without changing the protein structure, decreased the binding to LPS and partly reduced the ability of apoCI to stimulate the LPS-induced TNF/H9251 response (19).

However, in addition to the KVKEKLK motif, apoCI contains a number of alternating cationic/hydrophobic motifs throughout its structure. These motifs are also present in the proposed LPS-binding regions of other LPS-binding proteins albeit that apoCI (57 amino acids) is smaller than BPI (456 amino acids).

ApoCI has been demonstrated to act as a negative acute-phase protein after LPS administration and during bacterial sepsis (16–18), suggestive of a role of apoCI in inflammation and sepsis. Indeed, we recently showed that apoCI strongly binds to LPS, thereby prolonging the residence time of LPS in the circulation (19). In addition, apoCI stimulated the LPS-induced production of TNFα by macrophages in vitro and in mice in vivo. By enhancing the biological response toward LPS and Gram-negative bacteria, apoCI improved the antibacterial attack, reduced bacterial outgrowth, and protected against intrapulmonary Klebsiella pneumoniae-induced fatal sepsis (19). Moreover, by enhancing the systemic inflammatory state, apoCI aggravated LPS-induced atherosclerosis in hyperlipidemic apoE-deficient mice (20). We were able to extrapolate these findings to humans by showing that plasma apoCI levels positively correlate with an enhanced inflammatory response during endotoxemia (21) and with increased infection-related survival (17, 22).

We previously noted that the Lys-rich KVKEKLK motif (apoCI48–54) is highly homologous to the motifs in the proposed LPS-binding regions of the LPS-binding proteins Limulus anti-LPS factor (LALF) (LALF43-49; KWKYKGK) (23) and cationic antimicrobial peptide-18 (CAP-18) (CAP18117–123; KIKEKLK) (24) (Table 1). In fact, we have demonstrated that replacement of the Lys residues within this motif by Ala residues (i.e., AVAEALA), which neutralizes positive charges without changing the protein structure, decreased the binding to LPS and partly reduced the ability of apoCI to stimulate the LPS-induced TNFα response (19). However, in addition to the KVKEKLK motif, apoCI contains a number of alternating cationic/hydrophobic motifs throughout its structure. These motifs are also present in the proposed LPS-binding regions of other LPS-binding proteins.

| LPS-binding proteins (amino acids) | Amino Acid Sequence | Reference |
|-----------------------------------|---------------------|-----------|
| BPI (85–100)                      | NIKSGKWAKQRFLKM    | Little et al. (37) |
| LBP (84–99)                       | SJRVRQGRVKRSFFLKL  | Taylor et al. (25) |
| Lf (28–34)                        | RKRVGPP            | Elass-Rochard et al. (26) |
| ApoE (133–149)                     | LRVLRASHLRKLRKL    | Lynch et al. (27) |
| MD2 (119–132)                      | FSFKGKFSKGRK      | Mancek et al. (3) |
| CAP-18 (106–137)                   | GLLRKRLFKRNKKEKLLKKKGKIQGLLPKL | Larrick et al. (24) |
| LALF (32–50)                      | HYR/KPTFRRLKWKYKGK | Hoes et al. (23) |
| ApoCI (1–30)                      | TPDPYSSLRKLKEFGNTELKARELISRK |               |
| ApoCI (31–57)                      | QSELSAKMREWFSETFQKVEKLI  |               |

Modified from De Haas et al. (34).

a Boldface residues represent basic amino acids; italic residues represent hydrophobic amino acids; underlined amino acids represent a comparable amino acid region.

b The receptor-binding domain of apoE has not yet been described as a LPS-binding domain.

---

**Fig. 1.** Peptide sequences of apoCI1-57 and apoCI-derived peptides. The three-dimensional structure of apoCI (A) and the primary peptide sequences (B) are shown. Residues in boldface represent basic amino acids and residues in italics represent hydrophobic residues. The previously identified LPS-binding motif (residues 48–54) and the alternating cationic/hydrophobic motifs (residues 10–12, 21–23, 28–30, and 37–39) are boxed.
proteins, such as BPI, LPS-binding protein (LBP) (25), lactoferrin (Lf) (26), apoE (27), and MD2 (3) (Table 1). Similar to the previously identified LPS-binding motif of apoCI, these alternating cationic/hydrophobic motifs within apoCI are highly conserved during evolution (28) and may well be involved in the LPS-binding properties of apoCI.

In this study we aimed at analyzing the structure and function relationship of apoCI with respect to binding of LPS and modulating the response to LPS. In addition, we aimed at unraveling the mechanism by which apoCI enhances the LPS-induced inflammatory response. We designed and generated an array of N- and C-terminal apoCI-derived peptides containing the LPS-binding motif and/or a varying number of highly conserved alternating cationic/hydrophobic motifs. We demonstrate that peptides containing either the full N-terminal helix or the full C-terminal helix can bind LPS and enhance the inflammatory response toward LPS, albeit with reduced efficiency as compared with full-length apoCI. Furthermore, we show that apoCI stimulates the LPS-induced proinflammatory response via an LBP-like mechanism dependent on functional CD14/TLR4 signaling. We anticipate that in addition to the previously identified LPS-binding motif, the highly conserved alternating cationic/hydrophobic motifs present throughout the apoCI sequence participate in the binding to LPS and enhancement of the biological response to LPS via a mechanism similar to LBP.

MATERIALS AND METHODS

Animals
C57Bl/6 mice (own breeding) and TLR4-mutant (C3H/HeJ) and wild-type TLR4-expressing (C3H/HeN) mice from Jackson Laboratories (Bar Harbor, ME) were housed at the breeding facility of TNO-Quality of Life in a temperature- and humidity-controlled environment and were fed ad libitum with regular chow (Ssniff, Soest, Germany). All experiments were approved by the animal ethics committee of TNO or the Leiden University Medical Center. Experiments were conducted in male mice at 10–12 weeks of age.

Synthesis of apoCI-derived peptides
The synthesis of human apoCI-derived peptides was carried out by the Peptide Synthesis Facility of the Department of Immunohematology and Blood Transfusion at the Leiden University Medical Center (Leiden, The Netherlands) by solid phase peptide synthesis on a TentagelS-AC (Rap, Tübingen, Germany) using 9-fluorenylmethoxycarbonyl/t-Bu chemistry, benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate/N-methylpyrrolidone for activation, and 20% piperidine in 9-fluorenylmethoxycarbonyl/t-Bu chemistry, benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate/ N-methylmorpholino for purification. The purified peptides were analyzed by reversed phase-HPLC and their molecular masses were confirmed by MALDI-time-of-flight mass spectrometry (purity >95%). Synthesized full-length human apoCI (apoCI1–57; purity >95%) was obtained from Protein Chemistry Technology Center (UT Southwestern Medical Center, Dallas, TX).

Radiolabeling of LPS
Salmonella Minnesota Re595 LPS (Sigma-Aldrich Co., St. Louis, MO) was radiolabeled as described (30). Briefly, 1 mg of LPS was incubated with 4.6 mg methyl 4-hydroxybenzimidate hydrochloride (Fluka Chemie, Buchs, Switzerland) in 1 ml of 50 mM borate buffer (pH 8.5) for 18 h. After dialysis against PBS, 0.5 ml of the derivatized product was radiolabeled using 10 µL of 4 µg/ml chloramine T (Merck, Darmstadt, Germany) and 10 µL (0.25 mM) Nα125I (Amersham, Little Chalfont, UK). The reaction was stopped with 10 µL of 4 mg/ml Na2S2O4, and the radiiodinated product was dialyzed extensively against PBS (pH 7.4). Prior to experiments, the 125I-LPS was sonicated three times for 30 s, with 1 min intervals on ice in between, using a Soniprep 150 (MSE Scientific Instruments, Crawley, UK) at 10 µm output. The quality of the 125I-LPS was routinely checked by agarose gel electrophoresis. The specific activity of 125I-LPS was ~1.0 × 107 cpm/ng.

Agarose gel electrophoresis
125I-LPS (150 ng) was incubated (30 min, 37°C) in the absence or presence of apoCI-derived peptides or apoCI1–57 at the indicated molar ratios. Aliquots of incubation mixtures were subjected to electrophoresis in 0.75% (w/v) agarose gels at pH 8.8 using 70 mM Tris-HCl, 80 mM hippuric acid, 0.6 mM EDTA, and 250 mM NaOH buffer. Bromophenol blue (Merck) served as a front marker. For detection of 125I-LPS, gels were dried overnight at 65°C, exposed to a phosphorimaging plate (BAS-MS2040; Fuji Photo Film, Co. Ltd, Tokyo, Japan), and radioactivity was detected on a phosphor imaging analyzer (Fujix BAS-1000; Fuji Photo Film Co. Ltd.).

Serum residence and liver association of 125I-LPS
Mice were anesthetized by intraperitoneal injection of domitor (0.5 mg/kg; Pfizer, New York, NY), dormicur (5 mg/kg; Roche Netherlands, Mijdrecht, The Netherlands), and fentanyl (0.05 mg/kg; Janssen-Cilag B.V., Tilburg, The Netherlands) and the abdomens were opened. 125I-LPS (10 µg/kg) was injected via the vena cava inferior. Thirty minutes after injection, the serum residence and the liver association of 125I-LPS were determined. Blood samples (<50 µL) were taken from the vena cava inferior and allowed to clot for 30 min. The samples were centrifuged for 10 min at 7,000 rpm, and 20 µL serum samples were counted for 125I-radioactivity. The total amount of radioactive LPS in the serum was calculated using the equation: serum volume (ml) = 0.04706 × body weight (g) (31). At the same time, liver lobules were tied off, excised, weighed, and counted for radioactivity. Mice were killed and the remainder of the liver was excised and weighed. Uptake of 125I-LPS by the liver was corrected for the radioactivity in the serum assumed to be present in the liver (84.7 µL serum/g wet weight) (32).

Challenge of macrophages with LPS
RAW 264.7 cells, a murine macrophage cell line, were seeded into 24-well plates (1 × 104 cells/well) or 96-well plates (60 × 103 cells/well) and cultured overnight at 37°C in DMEM, 10% FBS, 1% pen/strep. Cells were washed with DMEM and incubated with LPS (1 ng/ml) that was preincubated (30 min 37°C) with or without apoCI-derived peptides, full-length apoCI1–57, or BSA at the indicated molar ratios, was injected via the vena cava inferior. 37°C. As controls, cells were incubated with apoCI-derived peptides or apoCI1–57 alone at the highest concentration used in combination with LPS. Where indicated, cells were preincubated with apoCI1–57 (0.05 and 5 µg/ml), anti-CD14 antibody, or isotype control monoclonal antibody (10 µg/ml; Biometec) for 30 min at 37°C. After 1 min intervals on ice in between, using a Soniprep 150 (MSE Scientific Instruments, Crawley, UK) at 10 µm output. The quality of the 125I-LPS was routinely checked by agarose gel electrophoresis. The specific activity of 125I-LPS was ~1.0 × 107 cpm/ng.
ELISA (BD Biosciences Pharmingen) according to the manufacturer’s instructions. Likewise, thioglycollate-elicited TLR4-mutant (C3H/HeJ) and wild-type TLR4-expressing (C3H/HeN) peritoneal macrophages from 12-week-old mice were seeded into 24-well plates (0.6 × 10⁶ cells/well) and cultured as described above. Cells were washed, incubated with LPS preincubated with or without apoCl₁₋₅₇ (10-fold molar excess), and TNFα was determined in the medium.

**Challenge of mice with LPS**

Mice were injected intravenously with LPS (25 µg/kg) preincubated (30 min at 37°C) without or with apoCl-derived peptides or apoCl₁₋₅₇ at a 60-fold and 5-fold molar excess of peptide, respectively, in saline containing 0.1% (w/v) BSA. Just after injection (t₀) and at the indicated times, blood samples were taken from the tail vein and stored on ice. Samples were centrifuged (4 min at 14,000 rpm), and TNFα levels were determined in the plasma using the commercially available mouse TNFα module set BMS607MST (Bender MedSystems, San Bruno, CA).

**Statistical analysis**

Data were analyzed using nonparametric Mann-Whitney U tests. P-values < 0.05 were considered significant.

**RESULTS**

**Design of apoCl-derived peptides**

To determine the structure and function relationship of apoCl with respect to binding of LPS and modulation of the in vivo behavior of LPS, we designed and generated five peptides derived from human apoCl. Three peptides contain the full N-terminal α-helix (i.e., apoCl₁₋₃₈, apoCl₁₋₃₀) or a part thereof (apoCl₁₋₂₃), and two peptides contain the full C-terminal α-helix (i.e., apoCl₃₅₋₅₇) or a part thereof (apoCl₄₆₋₅₇) (Fig. 1B). In addition to length, the N-terminal peptides differ from each other by the number of cationic/hydrophobic triads (residues 10–12, 21–23, and 28–30). Both C-terminal peptides contain the previously identified LPS-binding motif (residues 48–54) and differ by the presence of one cationic/hydrophobic triad (residues 37–39).

**Effect of apoCl-derived peptides on the electrophoretic mobility of ¹²⁵I-LPS**

To investigate the LPS-deaggregating properties of the apoCl-derived peptides in vitro, we incubated the peptides with ¹²⁵I-LPS and examined the electrophoretic mobility of the resulting radioactive complexes on agarose gel (Fig. 2). Whereas micellar ¹²⁵I-LPS alone did not migrate (Rf = 0), incubation of ¹²⁵I-LPS with full-length apoCl (apoCl₁₋₅₇) at a 1:1 molar ratio resulted in a shift of all ¹²⁵I-LPS toward the front of the gel (Rf = 0.95), confirming our previous findings (19). ApoCl₁₋₃₈, apoCl₁₋₃₀, and apoCl₃₅₋₅₇ showed reduced efficiency to deaggregate ¹²⁵I-LPS compared with apoCl₁₋₅₇. These peptides did not deaggregate ¹²⁵I-LPS at a 1:1 molar ratio but were effective at a 1:20 molar ratio. ApoCl₁₋₂₃ and apoCl₄₆₋₅₇ did not deaggregate ¹²⁵I-LPS at a 1:20 molar ratio (Fig. 2) nor at a 1:60 molar ratio (not shown).

**Effect of apoCl-derived peptides on the serum residence and liver association of ¹²⁵I-LPS**

To examine whether the LPS-deaggregating characteristics of the various peptides would be reflected in their ability to modulate the kinetics of LPS in vivo, ¹²⁵I-LPS was incubated with the peptides and intravenously injected into C57Bl/6 mice (Fig. 3). ¹²⁵I-LPS alone was rapidly cleared from serum and ~90% of the injected dose associated with the liver. ApoCl₁₋₅₇ almost completely prevented

**Fig. 2.** Effect of apoCl-derived peptides on the electrophoretic mobility of ¹²⁵I-LPS. ¹²⁵I-LPS (20 ng) was incubated without or with apoCl-derived peptides derived from the N-terminal helix (A) or the C-terminal helix (B) at 1:1 and 1:20 molar ratios. As a positive control, ¹²⁵I-LPS was incubated with apoCl₁₋₅₇ at a 1:1 molar ratio. Aliquots of the incubation mixtures (approximately 1 × 10⁵ cpm) were subjected to electrophoresis in an 0.75% (w/v) agarose gel at pH 8.8. The resulting gel was dried and assayed for radioactivity by autoradiography.
Structure-function analysis of the apoCI-LPS interaction

1947

Fig. 3. Effect of apoCI-derived peptides on the serum residence and liver association of 125I-LPS in vivo. 125I-LPS (10 µg/kg) was incubated (30 min at 37°C) without or with a 20-fold molar excess of apoCI-derived peptides of the N-terminal helix (A) or of the C-terminal helix (B). The mixtures were injected via the vena cava inferior into anesthetized C57Bl/6 mice, and the serum residence (left panels) and liver association (right panels) of 125I-LPS were determined at 30 min after injection. As a positive control, 125I-LPS was incubated with apoCI1–57 in a 1:1 molar ratio. Data are expressed as percentage of injected dose ± SD (n = 2–3).

Fig. 4. Dose-dependent effects of peptides containing the full N-terminal helix (apoCI1–30) and full C-terminal helix (apoCI35–57) on the serum residence and liver association of 125I-LPS. 125I-LPS (10 µg/kg) was incubated (30 min at 37°C) without or with apoCI1–30 (A) or apoCI35–57 (B) at the indicated molar ratios. The mixtures were injected via the vena cava inferior into anesthetized C57Bl/6 mice, and the serum residence (left panels) and liver association (right panels) of 125I-LPS were determined at 30 min after injection. As a positive control, 125I-LPS was incubated with apoCI1–57 in a 1:1 molar ratio. Data are expressed as percentage of injected dose ± SD (n = 2–3).

The dose dependency of the effect of apoCI1–30 (containing the full N-terminal helix) and apoCI35–57 (containing the full C-terminal helix) to modulate the kinetics of 125I-LPS was investigated in more detail (Fig. 3B). At a 20-fold molar excess, apoCI35–57 showed a modest increase of the serum residence and decrease of the liver association of 125I-LPS compared with the N-terminal peptides (Fig. 3B). At a 60-fold molar excess, apoCI35–57 was still approximately 3-fold less active than apoCI1–57 (Fig. 4B).

Taken together, it appears that the effects of these various apoCI-derived peptides on the in vivo kinetics of 125I-LPS indeed reflect their relative LPS-deaggregating properties (Fig. 2). Importantly, both the N- and C-terminal helix contain structural components to deaggregate LPS and modulate the kinetic behavior of LPS in vivo.

Effect of apoCI-derived peptides on the LPS-induced TNFα response in vitro

We previously showed that full-length apoCI1–57 increases the LPS-induced TNFα response both in vitro and in vivo (19). Therefore, we first determined the ability of the peptides to increase the LPS-induced TNFα response in murine RAW 264.7 macrophages compared with apoCI1–57 (Fig. 5). Incubation of macrophages with the peptides only did not result in detectable TNFα secretion in the medium (not shown).
ApoCI$_{1-57}$ enhanced the LPS-induced TNFα response approximately 3-fold and 24-fold at a 10-fold and 100-fold molar excess, respectively (Fig. 5A), in line with our previous observations (19). Preincubation of macrophages with 0.05 and 5 µg/ml apoCI$_{1-57}$ (comparable with a 100-fold and 10,000-fold molar excess, respectively) had no effect on the LPS-induced TNFα response (not shown). Both apoCI$_{1-30}$ (Fig. 5B) and apoCI$_{35-57}$ (Fig. 5C) also increased the LPS-induced TNFα response. However, approximately 10-fold more peptide was required to achieve the level of stimulation as observed with apoCI$_{1-57}$. ApoCI$_{1-50}$ was more effective than apoCI$_{35-57}$, in line with its more pronounced effect on deaggregation of LPS and modulation of the in vivo behavior of LPS.

**Effect of apoCI-derived peptides on the LPS-induced TNFα response in vivo**

Subsequently, we determined the ability of the peptides to increase the TNFα response after intravenous injection of LPS in C57Bl/6 mice in vivo. At a 5-fold molar excess, apoCI$_{1-57}$ enhanced the LPS-induced plasma TNFα levels 3.8-fold at 1 h after injection (Fig. 6A). Similarly to the in vitro macrophage stimulation studies, both apoCI$_{1-30}$ and apoCI$_{35-57}$ enhanced the LPS-induced TNFα response, albeit with reduced efficiency compared with apoCI$_{1-57}$. At a 60-fold molar excess, the LPS-induced TNFα response was increased by apoCI$_{1-30}$ (2.3-fold) and tended to be increased by apoCI$_{35-57}$ (1.8-fold).

Collectively, our findings indicate that both the N- and C-terminal helix contain structural components able to deaggregate LPS, modulate the in vivo behavior of LPS, and enhance the LPS-induced TNFα response in vitro and in vivo.

**Role of TLR4 in the stimulating effect of apoCI on the LPS-induced TNFα response in vitro and in vivo**

We evaluated whether apoCI and the apoCI-derived peptides augment the LPS-induced TNFα response via activation of TLR4, the signaling receptor of LPS. We stimulated peritoneal macrophages isolated from TLR4-mutant (C3H/HeJ) and wild-type TLR4-expressing (C3H/HeN) mice with LPS alone or in the presence of apoCI$_{1-57}$ (Fig. 7A). In wild-type macrophages, a 10-fold molar excess of apoCI$_{1-57}$ enhanced the LPS-induced TNFα response approximately 2-fold compared with LPS alone, which is comparable to the results obtained...
Role of CD14 in the stimulating effect of apoCI on the LPS-induced TNFα response in vitro

Finally, we studied the role of CD14 in the apoCI-mediated enhanced LPS-induced inflammatory response by blocking cell surface-bound CD14 using a CD14-specific antibody and by addition of sCD14. We preincubated RAW 264.7 macrophages with anti-CD14 antibody, followed by stimulation with LPS alone or in the presence of apoCI1–57 (Fig. 8A). Blocking CD14 almost completely inhibited the stimulating effect of apoCI on the LPS-induced TNFα response (up to 93%), while an isotype control antibody did not block the enhancing effect of apoCI1–57. In line with

Role of CD14 and LBP in the stimulating effect of apoCI on the LPS-induced TNFα response in vitro

Fig. 8. Role of CD14 and LBP in the stimulating effect of apoCI on the LPS-induced TNFα response in vitro. A: RAW 264.7 cells were preincubated (50 min at 37°C) in DMEM supplemented with 0.01% human serum albumin and vehicle (white bars), isotype control antibody (gray bars), or anti-CD14 antibody (black bars), washed, and subsequently incubated (4 h at 37°C), in DMEM supplemented with 0.01% human serum albumin, with LPS (1 ng/ml) that was preincubated (30 min at 37°C) without or with a 100-fold molar excess of apoCI1–57. TNFα was determined in the medium by ELISA. B, C: RAW 264.7 cells were incubated (4 h at 37°C), in DMEM supplemented with 0.01% human serum albumin, with LPS (1 ng/ml) that was preincubated (30 min at 37°C) without or with a 100-fold molar excess of apoCI1–57 in the presence of soluble CD14 (sCD14) (B) or LBP (C). TNFα was determined in the medium by ELISA. Data are expressed as mean TNFα concentration ± SD (n = 3–4). *P < 0.05 compared with vehicle (A) or LPS alone (B, C); #P < 0.05 compared with control antibody.
this finding, the addition of increasing concentrations of sCD14 to a fixed concentration of apoCI (100-fold molar excess over LPS) strongly augmented the apoCI-mediated enhanced LPS-induced TNFα response (Fig. 8B). In fact, whereas addition of apoCI1-37 alone induced LPS-induced TNFα levels up to 16.5 ± 1.2 ng/ml, which is comparable to apoCI1-57 (20.2 ± 1.2 ng/ml). However, the combination of apoCI1-57 with LBP at most additively stimulated the LPS-induced TNFα response up to only 30.8 ± 1.3 ng/ml. Together, these findings indicate that apoCI does not interact with LBP but suggest that apoCI augments the LPS-induced inflammatory response via a similar mechanism as LBP does, by presenting the LPS to CD14, which ultimately transfers the LPS to the MD2/TLR4 complex.

DISCUSSION

We recently identified apoCI as an LPS-binding protein, with an apparent LPS-binding motif in its C-terminal helix, that acts as a biological enhancer of the proinflammatory response toward LPS (19). Because apoCI contains several highly conserved alternating cationic/hydrophobic motifs throughout its structure that may cooperate in LPS binding, we further investigated the structure and function relationship of apoCI with respect to its ability to bind LPS, to modulate the in vivo behavior of LPS, and to stimulate the proinflammatory response to LPS. In addition, we studied the mechanism by which apoCI enhances the LPS-induced inflammatory response. We designed and generated an array of N- and C-terminal apoCI-derived peptides containing the apparent LPS-binding motif and/or varying numbers of the cationic/hydrophobic motifs. We demonstrate that apoCI contains additional structural elements, in addition to the LPS-binding motif, that enable it to bind LPS and enhance the CD14/TLR4-dependent inflammatory response toward LPS via a mechanism similar to LBP.

Our previous studies showed that the binding of apoCI to LPS was largely mediated by a Lys-rich LPS-binding motif in the C terminus of apoCI (KVKEKL; residues 48–54), which is highly homologous to the LPS-binding motif of LALF (23) and CAP-18 (24). Replacement of the Lys residues by Ala within this motif did decrease the ability of apoCI to bind LPS (19), but the binding to LPS was not abrogated completely. The mutant peptide was still able to modulate the in vivo kinetics of LPS to some extent (19), which indicated that apoCI should contain additional elements that cooperate in LPS binding. We now demonstrated that apoCI1-30, apoCI1-38, and apoCI35-57, all deggregated LPS, prevented the uptake of LPS by the liver, prolonged the residence time of LPS in the serum, and enhanced the LPS-induced TNFα response. These findings indicate that both the N- and C-terminal helix contain additional structural elements that can deaggregate LPS and enhance the inflammatory response toward LPS.

To evaluate whether these apoCI-derived peptides were able to bind LPS, we determined the ability of the peptides to alter the electrophoretic mobility of [125I]LPS. Although we clearly showed that apoCI1-30, apoCI1-38, and apoCI35-57 deaggregated LPS, we were unable to show colocalization of the peptides with [125I]LPS, because the binding affinity of the detecting anti-apoCI antibody was abrogated upon any truncation of full-length apoCI. However, because we previously showed that full-length apoCI firmly bound LPS and colocalized with LPS (19), it is very likely that the LPS-deaggregation potential of the various apoCI-derived peptides reflect their LPS-binding potential. These findings are in line with the hypothesis of Frecer et al. (33), who suggested, by using molecular modeling methods, that any peptide containing cationic/hydrophobic motifs within their sequence will recognize and bind LPS with high affinity. Indeed, such motifs are also involved in the interaction of, for instance, Lf and BPI with LPS (34). Our observations that apoCI-derived peptides containing the N-terminal helix without the previously established LPS-binding motif (i.e., apoCI1-30 and apoCI1-38) alter the in vivo behavior of LPS and increase the LPS-induced TNFα response are, therefore, likely explained by the presence of such amphipathic motifs.

The efficiencies of the apoCI-derived peptides to bind LPS and modulate the inflammatory response toward LPS were lower compared with full-length apoCI1-57. It is likely that the structural elements in both helices, represented by the alternating cationic/hydrophobic peptide motifs, act synergistically in the binding of LPS. A similar synergistic interaction with LPS has previously been demonstrated for Lf (35) and sheep myeloid antimicrobial peptide-29 (36), a sheep myeloid antimicrobial peptide, which both have two LPS-binding domains, and BPI (37) and serum amyloid P (34), which both have three regions that contribute to binding to LPS.

It is intriguing to speculate how apoCI interacts with LPS and enhances the LPS-induced proinflammatory response. LPS consists of four different moieties: 1) lipid A, the toxic moiety, 2) the inner core, 3) the outer core, and 4) the O-antigen. We previously reported that apoCI interacts with different forms of LPS from Salmonella minnesota [i.e., full-length wild-type LPS, and the truncated Re595 LPS, containing the lipid A moiety and some KDO sugars (19)], but more recently we also found that apoCI interacts with different types of LPS from Escherichia coli [i.e., O55:B5 LPS (20) and J5 LPS (Berbée and Rensen, unpublished observations)]. ApoCI thus interacts with both full-length, wild-type LPS and truncated forms of LPS, which indicates that the lipid A/KDO moiety of the LPS molecule contains the crucial elements for interaction with apoCI. Because apoCI is highly positively charged, we hypothesize that the amphipathic motifs within apoCI interact with the lipid A moiety via the negatively charged
phosphate groups. Indeed, we found that apoCI interacts with the lipid A moiety. Similar to the effect of apoCI on the serum residence and liver uptake of $^{125}$I-LPS, apoCI markedly enhanced the serum residence of $^{125}$I-lipid A (29.7 ± 0.3% compared with 2.2 ± 0.4% for $^{125}$I-lipid A alone) and inhibited the liver uptake (36.3 ± 0.6% vs. 66.5 ± 6.0%) at a 1:1 molar ratio (not shown). Because lipid A is the common determinant of LPS molecules from all bacterial species, apoCI is likely to bind a wide array of wild-type and mutant LPS molecules.

ApoCI is able to enhance the proinflammatory response toward LPS via a direct interaction with LPS in vitro and in vivo. Thus far, other proteins that have been reported to bind LPS (e.g., serum amyloid P, apoE, Lf, and LALF) attenuate rather than stimulate the LPS-induced inflammatory response, except for LBP and CD14, which are required for LPS signaling (38, 39). We conclusively demonstrate by using TLR4-mutant mice that apoCI augments the LPS response by enhancing TLR4-dependent signaling. Although the LDL receptor (40, 41) and scavenger receptors, such as scavenger receptor class A (42–44) and BI (45–47), modulate inflammatory responses to LPS, these receptors apparently are not involved in the stimulating effect of apoCI on the LPS response. Next to TLR4, we show that the stimulating effect of apoCI is also dependent on functional CD14. An anti-CD14 antibody completely blocked the augmenting effect of apoCI, whereas co-incubation with sCD14 synergistically enhanced the effect of apoCI on the LPS-induced inflammatory response. Interestingly, co-incubation experiments of apoCI with LBP indicate that apoCI augments the LPS-induced inflammatory response via a similar mechanism as LBP does, by presenting the LPS toward CD14. Based on these findings, we now propose the following mechanism. Plasma apoCI, either bound to lipoproteins or moving freely in plasma, interacts with the lipid A part of LPS, presumably via the negatively charged phosphate groups, and subsequently transfers the LPS to either membrane-bound CD14 or sCD14, which ultimately presents the LPS to the MD2/TLR4 complex, thereby activating the TLR4-dependent inflammatory response.

In summary, we have demonstrated that apoCI contains structural elements in both its N-terminal and C-terminal helix to bind LPS, to modulate the in vivo behavior of LPS, and to enhance the TLR4-dependent proinflammatory response toward LPS in vitro and in vivo via an LBP-like mechanism. We anticipate that, in addition to the previously identified LPS-binding motif, the highly conserved alternating cationic/hydrophobic motifs present throughout the apoCI sequence participate in the binding to LPS and enhance the biological response to LPS.

REFERENCES

1. Harris, R. L., D. M. Mushker, K. Bloom, J. Gathe, L. Rice, B. Sugarman, T. W. Williams, Jr., and E. J. Young. 1987. Manifestations of sepsis. Arch. Intern. Med. 147: 1895–1906.

2. Poltorak, A., X. He, J. Smirnova, M. Y. Liu, C. van Huffel, X. Du, D. Birdwell, E. Alejos, M. Silva, C. Galanos, et al. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Thr4 gene. Science. 282: 2085–2088.

3. Shimazu, R., S. Akashi, H. Ogata, Y. Nagai, K. Fukudome, K. Miyake, and M. Kimoto. 1999. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J. Exp. Med. 189: 1777–1782.

4. Nagai, Y., S. Akashi, M. Nagafuku, M. Ogata, Y. Iwakura, S. Akira, T. Kimataura, A. Kosugi, M. Kimoto, and K. Miyake. 2002. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat. Immunol. 3: 667–672.

5. Kobayashi, M., S. Saitoh, N. Tanimura, K. Takahashi, K. Kawasaki, M. Nishijima, Y. Fujimoto, K. Fukase, S. Akashi-Takamura, and K. Miyake. 2006. Regulatory roles for MD-2 and TLR4 in ligand-induced receptor clustering. J. Immunol. 176: 6211–6218.

6. Manceck, M., P. Pritovic, and R. Jerala. 2002. Identification of LPS-binding peptide fragment of MD-2, a toll-receptor accessory protein. Biochem. Biophys. Res. Commun. 292: 880–885.

7. Netea, M. G., J. W. van der Meer, M. van Deuren, and B. J. Kullberg. 2003. Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing? Trends Immunol. 24: 254–258.

8. Bone, R. C. 1991. The pathogenesis of sepsis. Ann. Intern. Med. 115: 457–469.

9. Bone, R. C., C. J. Grodzin, and R. A. Balk. 1997. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest. 112: 235–245.

10. Berbee, J. F., C. C. van der Hoort, D. Sundaramaran, L. M. Havekes, and P. C. Rensen. 2005. Severe hypertriglyceridermia in human APOCI transgenic mice is caused by apoC-I-induced inhibition of LPL. J. Lipid Res. 46: 297–306.

11. Havel, R. J., C. J. Fielding, T. Oliveira, V. G. Shore, P. E. Fielding, and T. Egelrud. 1973. Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglycerides by lipoproteins lipase from different sources. Biochemistry. 12: 1828–1833.

12. Sehayek, E., and S. Eisenberg. 1991. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J. Biol. Chem. 266: 18295–18297.

13. Weisgraber, K. H., R. W. Mahley, R. C. Kowal, J. Herz, J. L. Goldstein, and M. S. Brown. 1990. Apolipoprotein C-I modulates the interaction of apolipoprotein E with beta-migrating very low density lipoproteins (beta-VLDL) and inhibits binding of beta-VLDL to low density lipoprotein receptor-related protein. J. Biol. Chem. 265: 22453–22459.

14. Beamer, L. J., S. F. Carroll, and D. Eisenberg. 1997. Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution. Science. 276: 1861–1864.

15. Rozeck, A., J. T. Sparrow, K. H. Weisgraber, and R. J. Cushek. 1998. Conformation of human apolipoprotein C–I in a lipid-mimetic environment determined by CD and NMR spectroscopy. Biochemistry. 38: 14475–14484.

16. Barlage, S., D. Frohlich, A. Bottcher, M. Jauhiainen, H. P. Muller, F. Noetzel, G. Rothe, C. Schutt, R. P. Linke, K. J. Lackner, et al. 2001. ApoE-containing high density lipoproteins and phospholipid transfer protein activity increase in patients with a systemic inflammatory response. J. Lipid Res. 42: 281–290.

17. Berbee, J. F., C. C. van der Hoort, C. J. de Haas, K. P. van Kessel, G. M. Dallinga-Thie, J. A. Romijn, L. M. Havekes, H. J. van Leeuwen, and P. C. Rensen. 2008. Plasma apolipoprotein C1 correlates with increased survival in patients with severe sepsis. Intensive Care Med. 34: 907–911.

18. Li, L., P. A. Thompson, and R. L. Kitchens. 2008. Infection induces a positive acute phase apolipoprotein E response from a negative acute phase gene: role of hepatic LDL receptors. J. Lipid Res. 49: 1782–1793.

19. Berbee, J. F., C. C. van der Hoort, R. Kleemann, E. F. Schippers, R. L. Kitchens, J. T. van Dissel, I. A. Bakker-Woudenberg, L. M. Havekes, and P. C. Rensen. 2006. Apolipoprotein CI stimulates the response to lipopolysaccharide and reduces mortality in Gram-negative sepsis. FASEB J. 20: 2162–2164.

20. Westerterp, M., J. F. Berbee, N. M. Pires, G. J. M. van Mierlo, R. Kleemann, J. A. Romijn, L. M. Havekes, and P. C. Rensen. 2007. Apolipoprotein C–I is crucially involved in lipopolysaccharide-induced atherosclerosis development in apolipoprotein E-knockout mice. Circulation. 116: 2173–2181.

21. Schippers, E. F., J. F. Berbee, I. M. van Disseldorp, M. I. Versteegh, L. M. Havekes, P. C. Rensen, and J. T. van Dissel. 2008. Preoperative Structure-function analysis of the apoCI-LPS interaction.
apolipoprotein C1 levels correlate positively with the proinflammatory response in patients experiencing endotoxemia following elective cardiac surgery. *Intensive Care Med.* **34**: 1492–1497.

22. Berbee, J. F., S. P. Mooijaart, A. J. de Craen, L. M. Havekes, D. van Heemst, P. C. Rensen, and R. G. Westendorp. 2008. Plasma apolipoprotein C1 protects against mortality from infection in old age. *J. Gerontol. A Biol. Sci. Med. Sci.* **63**: 122–126.

23. Hoess, A., S. Watson, G. R. Sierra, and R. Liddington. 1993. Crystal structure of an endotoxin-neutralizing protein from the horseshoe crab, Limulus anti-LPS factor, at 1.5 Å resolution. *EMBO J.* **12**: 3533–3556.

24. Larrick, J. W., M. Hirata, H. Zheng, J. Zhong, D. Bolin, J. M. Cavaillon, H. S. Warren, and S. C. Wright. 1994. A novel granulocyte-derived peptide with lipopolysaccharide-neutralizing activity. *J. Immunol.* **152**: 231–240.

25. Taylor, A. H., G. Heavner, M. Nedelman, D. Brunt, D. Knight, and J. Ghayeb. 1995. Lipopolysaccharide (LPS) neutralizing peptides reveal a lipid A binding site of LPS binding protein. *J. Biol. Chem.* **270**: 17034–17038.

26. Elss-Rochard, E., A. Roseanu, D. Legrand, M. Trif, V. Salmon, C. Motas, J. Montreuil, and G. Spik. 1995. Lactoferrin-lipopolysaccharide interaction: involvement of the 28–34 loop region of human lactoferrin in the high-affinity binding to Escherichia coli 055B5 lipopolysaccharide. *Biochem. J.* **312**: 839–845.

27. Lynch, J. R., W. Tang, H. Wang, M. P. Vitek, E. R. Bennett, P. M. Sullivan, D. S. Warner, and D. T. Laskowitz. 2003. APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. *J. Biol. Chem.* **278**: 48529–48533.

28. Hoffer, M. J., M. M. van Eck, L. M. Havekes, M. H. Hoffer, and R. R. Frants. 1993. The mouse apolipoprotein C1 gene: structure and expression. *Genomics.* **18**: 37–42.

29. Tjabringa, G. S., J. Aarbou, D. K. Nihaner, J. W. Drijfhout, O. E. Sorensen, N. Borregaard, K. F. Rabe, and P. S. Heimstra. 2003. The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. *J. Immunol.* **171**: 6690–6696.

30. Ulevitch, R. J. 1978. The preparation and characterization of a radiolabeled bacterial lipopolysaccharide. *Immunochemistry.* **15**: 157–164.

31. Jong, M. C., P. C. Rensen, V. E. Dahlmans, H. van der Boom, T. J. van Berkel, and L. M. Havekes. 2001. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. *J. Lipid Res.* **42**: 1576–1585.

32. Rensen, P. C., N. Herijgers, M. H. Netscher, S. C. Meskers, M. van Eck, and T. J. van Berkel. 1997. Particle size determines the specificity of apolipoprotein E-containing triglyceride-rich emulsions for the LDL receptor versus hepatic remnant receptor in vivo. *J. Lipid Res.* **38**: 1070–1084.

33. Freer, V., B. Ho, and J. L. Ding. 2000. Interpretation of biological activity data of bacterial endotoxins by simple molecular models of mechanism of action. *Eur. J. Biochem.* **267**: 837–852.

34. De Haas, C. J., R. van der Zee, B. Benaissa-Trouw, K. P. van Kessel, J. Verhoef, and J. A. van Strijp. 1999. Lipopolysaccharide (LPS)-binding synthetic peptides derived from serum amyloid P component neutralize LPS. *Infect. Immun.* **67**: 2790–2796.

35. Elss-Rochard, E., D. Legrand, V. Salmon, A. Roseanu, M. Trif, P. S. Tobias, J. Mazurier, and G. Spik. 1998. Lactoferrin inhibits the endotoxin interaction with CD14 by competition with the lipopolysaccharide-binding protein. *Infect. Immun.* **66**: 486–491.

36. Tack, B. F., M. V. Sawai, W. R. Kearney, A. D. Robertson, M. A. Sherman, W. Wang, T. Hong, L. M. Boo, H. Wu, A. J. Waring, et al. 2002. SMAP-29 has two LPS-binding sites and a central hinge. *Eur. J. Biochem.* **269**: 1181–1189.

37. Little, R. G., D. N. Kelner, E. Lim, D. J. Burke, and P. J. Conlon. 1994. Functional domains of recombinant bactericidal/permeability increasing protein (rBPI25). *J. Biol. Chem.* **269**: 1865–1872.

38. Ulevitch, R. J., and P. S. Tobias. 1994. Recognition of endotoxin by cells leading to transmembrane signaling. *Curr. Opin. Immunol.* **6**: 125–130.

39. Ulevitch, R. J., and P. S. Tobias. 1995. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. *Annu. Rev. Immunol.* **13**: 437–457.

40. Netea, M. G., P. N. Demacker, B. J. Kullberg, O. C. Boerman, I. Verschueren, A. F. Stalenhoef, and J. W. van der Meer. 1996. Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections. *J. Clin. Invest.* **97**: 1366–1372.

41. Van den Elzen, P., S. Garg, L. Leon, M. Brigl, E. A. Leadbetter, J. E. Sullivan, D. S. Warner, and D. T. Laskowitz. 2003. APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. *Nature.* **437**: 906–910.

42. Suzuki, H., Y. Kurihara, M. Takeya, N. Kamada, M. Kataoka, K. Jishage, O. Ueda, H. Sakaguchi, T. Higashi, T. Suzuki, et al. 1997. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. *Nature.* **386**: 292–296.

43. Hampton, R. Y., D. T. Golenbock, M. Penman, M. Krieger, and C. R. Raetz. 1991. Recognition and plasma clearance of endotoxin by scavenger receptors. *Nature.* **352**: 342–344.

44. Haworth, R., N. Platt, S. Keshav, D. Hughes, E. Darley, H. Suzuki, Y. Kurihara, T. Kodama, and S. Gordon. 1997. The macrophage scavenger receptor type A is expressed by activated macrophages and protects the host against lethal endotoxic shock. *J. Exp. Med.* **186**: 1431–1439.

45. Bocharov, A. V., I. N. Baranova, T. G. Vishnyakova, A. T. Remaley, G. Csako, F. Thomas, A. P. Patterson, and T. L. Eggerman. 2004. Targeting of scavenger receptor class B type I by synthetic amphipathic alpha-helical-containing peptides blocks lipopolysaccharide (LPS) uptake and LPS-induced pro-inflammatory cytokine responses in THP-1 monocyte cells. *J. Biol. Chem.* **279**: 36072–36082.

46. Li, X. A., L. Guo, R. Asmis, M. Nikolova-Karakashian, and E. J. Smart. 2006. Scavenger receptor BI prevents nitric oxide-induced cytotoxicity and endotoxin-induced death. *Cir. Res.* **98**: e60–e65.

47. Vishnyakova, T. G., A. V. Bocharov, I. N. Baranova, Z. Chen, A. T. Remaley, G. Csako, T. L. Eggerman, and A. P. Patterson. 2003. Binding and internalization of lipopolysaccharide by Cla-1, a human orthologue of rodent scavenger receptor BI. *J. Biol. Chem.* **278**: 22771–22780.